Alcon Science Resource Library
Cataract Diagnostics and Equipment
IOLs for managing presbyopia try to achieve a balance between increasing the range of vision, with the goal of spectacle independence, and reducing visual phenomena associated with the various optical designs. Some surgeons…
Cataract Diagnostics and Equipment
Hisaharu Suzuki, MD, PhD clinical study video: Anterior Chamber Stability of a Novel Phacomulsification Machine via the Slit Side View Method
Intraocular Lenses
Robert Melendez, MD, MBA clinical study video: Post-Operative Chair Time Requirement for Advanced Technology Intraocular Lenses: A Real-World, Prospective, Comparative, Observarional Study
Refractive Surgery
John Kanellopoulos, MD, ABO, shares insights on the international multicentre study evaluating femtosecond-laser assisted myopic LASIK customised by automated ray-tracing for low and high order aberrations.
Cataract Diagnostics and Equipment
A conversation of two expert cataract refractive surgeons with an audience of peer surgeons. At the AAO meeting in Chicago in October 2024, Cathleen McCabe, MD, and Nicole Fram, MD, hosted a dinner discussion on performing…
Dry Eye
Dr Katherine Bickle, OD, PhD, presents this clinical research summary video on rapid, lasting relief of dry eye symptoms with propylene glycol-hydroxypropyl-guar-hyaluronic acid nanoemulsion lubricant preservative-free eye…
Dry Eye
Dr Walter Whitley, OD, MBA, FAAO, presents this clinical research summary video on tear production associated with a novel TRPM8 agonist (AR-15112), sharing results from Phase 3 pivotal clinical studies COMET-2 and COMET-3.
Dry Eye
Dr Nate Lightizer, OD, presents this clinical research summary video on how Acoltremon 0.0003% leads to a statistically significant increase in tear volume and tear total lipid concentration, based on Phase 3b study results.
Dry Eye
Dr Cory Lappin, OD, MS, FAAO, presents this clinical research summary video examining improvement in visual tasking activities and workplace productivity after 14 days of Acoltremon 0.0003% treatment, based on an integrated…